Refills advertises personalized GLP-1 care from $5 a day, with no separate monthly membership or app fee. That is a starting point for a cost conversation, but it leaves the actual subscription term to confirm. A daily headline is not the same thing as the amount due when an order is placed.
We checked the current Refills website, product descriptions, terms, return policy, FAQ and FDA record on October 15, 2026. We did not enter medical details, complete a purchase or test a prescription. This review keeps the company’s promises, its written conditions and the regulator’s findings in separate view.
One thing to keep with you
Ask for the exact recurring charge and processing date. The FAQ’s broad cancellation wording sits alongside a 72-hour deadline in the terms, and an FDA warning letter supplies relevant context for the marketing claims.
The headline does not provide a complete invoice
The homepage and personalized GLP-1 product page advertise a starting figure of $5 per day. The site also displays a percentage-off promotion. We did not verify the selected checkout’s introductory charge, renewal amount or prepaid commitment, so this review does not convert the headline into a quoted monthly subscription price.
Refills says doses have the same price and promotes free shipping and no monthly membership or app fee. Its terms explain that a subscription’s total can include pharmacy charges, professional services and platform fees. A bundled fee is different from an extra charge added to the advertised total; request an itemized explanation if the final amount is unclear.
The cost guide provides a way to compare complete payments. Record the medication, supply period, amount collected today and recurring interval together. A low daily equivalent is not enough to compare two plans.
Checked with: Refills: advertised program · Refills: personalized GLP-1 product page · Refills: terms updated June 2, 2026
The platform is separate from the prescriber and pharmacy
Refills Health LLC describes itself as a technology and administrative platform, not a medical practice or dispensing pharmacy. Its disclosures identify independent clinical partners, including Beluga Health, Bask Health and Wasef Health; the homepage also mentions TelegraMD. The professional entity and pharmacy assigned to an individual prescription need to be identified in that person’s care documents.
The current terms describe the service as cash-pay outside insurance reimbursement programs. The homepage says it operates in all 50 states but not Washington, DC, while the FAQ makes availability dependent on product and pharmacy coverage. Confirm that the actual medicine and clinical service are available where you receive care.
The product descriptions concern compounded preparations. The phrase personalized GLP-1 does not identify every ingredient or establish FDA approval. Ask for the exact prescription and pharmacy information, using our compounding questions as preparation.
Checked with: Refills: advertised program · Refills: terms updated June 2, 2026 · Refills: subscriptions, support and shipping FAQ · Refills: personalized GLP-1 product page · FDA: concerns about unapproved GLP-1 products
Cancel-anytime wording still has a processing deadline
The FAQ says a member can pause, skip or cancel through the account dashboard without a long-term commitment. The June 2, 2026 terms specify cancellation up to 72 hours before the applicable monthly processing date, through the account or email. Read that deadline alongside the general promise and save the request confirmation.
The return policy says prescription sales become final after payment has been charged and the parcel handed to the carrier. It also tells members to make account or subscription changes before the product is sent to the pharmacy. Stopping future renewals and reversing a current order are separate requests.
The policy describes contacting support about damaged medication and reshipping lost orders after working with the carrier. It does not provide an unconditional medication money-back guarantee. The separate 30-day return provision concerns unopened nonprescription products, so it should not be applied to a prescription order.
Checked with: Refills: subscriptions, support and shipping FAQ · Refills: terms updated June 2, 2026 · Refills: returns and fulfillment policy
A concierge message is not a measured clinician response
Refills advertises a 24-hour health concierge. Its FAQ directs nonmedical account and delivery questions to customer support and clinical questions to the clinical messaging route available under the plan. Those are different services; a concierge availability statement does not establish around-the-clock prescriber access.
The homepage describes a first consultation within a few days, while the FAQ says review can often occur within hours depending on demand and state coverage. Its shipping FAQ estimates arrival three to five business days after approval and pharmacy processing. We did not measure these timelines. Ask which event starts the estimate and how to reach the responsible clinician when a medical concern cannot wait for routine messaging.
Checked with: Refills: advertised program · Refills: subscriptions, support and shipping FAQ
What FDA said in February 2026
FDA’s February 20, 2026 warning letter addressed the Refills website reviewed in December 2025. The agency said pictured branding suggested Refills compounded the drugs when it did not, and objected to claims implying approval or established safety and effectiveness for compounded semaglutide.
The letter requested corrective action and an opportunity for the company to respond. It is a regulatory record about the identified marketing, not an independent assessment of every patient’s care. This review does not establish a later resolution.
Today’s site includes a disclaimer that compounded medications have not been approved or evaluated by FDA. That disclosure does not make them approved equivalents. The Lovely Meds review examines another offer where the price term and the regulatory record both deserve attention.
Checked with: FDA: Refills Health warning letter, February 20, 2026 · Refills: advertised program · FDA: concerns about unapproved GLP-1 products
Where we checked the facts
- Refills: advertised program
Checked October 15, 2026. Company-published offer or policy; not independent evidence of clinical results. Selected terms and availability can change.
- Refills: personalized GLP-1 product page
Checked October 15, 2026. Company-published offer or policy; not independent evidence of clinical results. Selected terms and availability can change.
- Refills: terms updated June 2, 2026
Checked October 15, 2026. Company-published offer or policy; not independent evidence of clinical results. Selected terms and availability can change.
- Refills: subscriptions, support and shipping FAQ
Checked October 15, 2026. Company-published offer or policy; not independent evidence of clinical results. Selected terms and availability can change.
- FDA: concerns about unapproved GLP-1 products
Current concerns include unapproved products, salt forms and adverse events. Compounding is not equivalent to generic approval.
- Refills: returns and fulfillment policy
Checked October 15, 2026. Company-published offer or policy; not independent evidence of clinical results. Selected terms and availability can change.
- FDA: Refills Health warning letter, February 20, 2026
Checked October 15, 2026. Original regulatory record; not a patient-outcome study or confirmation of subsequent resolution.
